Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia (NCT00060346), a na phase 2 study. The primary outcome is Objective Response to Treatment.

2. Clinical Question

This is a question about a defined laboratory-based response criterion in a treated group, not a randomized comparison of treatment strategies. The trial title describes a phase II pilot study, and the registry lists one primary outcome measure. The available record does not report how many eligible and treated patients contributed data to the endpoint, beyond the stated analysis population description. It also does not report participant characteristics that would help assess how closely the enrolled group represents the broader population of people with newly diagnosed Waldenstrom's macroglobulinemia.

3. Trial Design

The registry describes a phase II, single-group study with no masking. Allocation is listed as NA, consistent with the record's lack of a separate randomized treatment group. The study title calls it a pilot study. Enrollment is listed as 16, and the sponsor is Eastern Cooperative Oncology Group. The study start is recorded as 2004-10-05, primary completion as 2011-12, and status as terminated. The reason for termination is not reported in the registry record.

The active regimen is called Rituximab + CHOP. The listed intervention agents are rituximab, cyclophosphamide, doxorubicin, prednisone, and vincristine. The regimen description gives rituximab 375 mg/m2 on day 1 of a 21-day cycle, followed by cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, and prednisone 100 mg/m2 daily. Additional details about how long or how often the chemotherapy agents were given are not reported in the registry record.

A single-group design can describe outcomes among participants who received the regimen, but it does not create a concurrent control for separating treatment effects from other explanations for observed changes. For instance, without another group followed under a different strategy, the record cannot establish what the same participants' outcomes would have been under that strategy. This is a design limitation, not a finding about the regimen.

The registry names one primary outcome measure: objective response to treatment. Its timing description calls for assessment every 3 months if a patient is less than 2 years from study entry, every 6 months if 2-5 years from entry, and every 12 months if 6-10 years from entry. Whether these assessments were all completed, and how the stated timing was applied in practice, is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All eligible and treated patients are included in this analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Objective Response to Treatment, measured over Every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, every 12 months if patient is 6-10 years from study entry.

The primary endpoint is objective response to treatment, expressed as a proportion of participants. The registry defines response as a reduction greater than 50% in quantitative IgM or M-Spike levels from baseline. It further requires the response to be documented by two measurements separated by at least 3 weeks. The assessment is described as using standard myeloma response criteria.

This type of endpoint turns a continuous laboratory measure into a response category: each participant either meets the stated response definition or does not. Reporting a proportion can make the frequency of meeting a prespecified clinical or biological criterion easier to communicate than listing each participant's laboratory measurements. It also depends on the definition, measurement schedule, baseline values, and completeness of follow-up. These are general properties of a binary response endpoint; the registry record does not report individual measurements or how missing measurements were handled.

The stated follow-up schedule varies with time since study entry, from every 3 months for patients less than 2 years from entry to every 12 months for patients 6-10 years from entry. The registry says all eligible and treated patients are included in the analysis. However, it does not report the number meeting the response definition, the response proportion, or the specified 90% confidence interval. Thus, the endpoint definition is available, but its observed result is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a single-group design estimate?

In general, a single-group study records outcomes among people receiving one intervention. For a binary endpoint such as objective response, an analysis can estimate the proportion meeting the response definition. That estimate describes the observed group; it is not a treatment-versus-control effect because there is no separate comparator group. The registry lists the model as single-group, allocation as NA, and masking as none. It does not report a comparative analysis.

The distinction between a group outcome and a comparative effect matters. A response can occur for reasons that a one-group design cannot separate from the effect of the intervention, including features of the participants or the course of the condition. This is a general design consideration, not a claim about what happened in this study. The record supplies no basis for estimating a counterfactual outcome or making an adjusted comparison.

What does the response rule classify?

The endpoint is binary at the participant level: the stated rule classifies a participant as having an objective response when quantitative IgM or M-Spike levels fall by more than 50% from baseline and the response is documented by two measurements separated by at least 3 weeks. In general, turning measurements into a binary outcome makes the result easier to express as a proportion, but it also means that measurements near the cutoff can be classified differently from measurements that are far from it. The registry does not report participant-level values or borderline cases.

The listed measurement schedule changes with time since entry. In general, outcome timing can affect how often a response is assessed and whether it is observed at a particular follow-up point. The record gives the schedule but does not report actual assessment dates, adherence to the schedule, or whether response was evaluated at a fixed time point or across follow-up.

How should a confidence interval be read?

The primary outcome specifies a 90% confidence interval. In general, a confidence interval is a range of values compatible with the observed data under the analysis method. It communicates uncertainty around an estimate; it does not guarantee that the true value lies in that particular interval, and it does not correct for limitations in study design or data collection. A confidence interval is informative only when the estimate and interval are reported. Neither is reported in the registry record.

For a proportion, precision depends in part on how much information is available and on the observed response frequency. General statistical reasoning suggests that sparse data can leave substantial uncertainty, but the registry record does not give the number of endpoint events or the number with evaluable data. No precision assessment specific to this study can therefore be made from the endpoint information alone.

What do the planning assumptions mean?

The record describes sample-size calculations as planning illustrations based on the observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says the effect to detect is a stated fraction of the observed effect, and that non-time-to-event illustrations are expressed as participants per arm for 80% power or other listed planning levels. These are planning assumptions, not observed trial results. They do not indicate the study's actual power, and they are not the trial's own design justification.

General explanation: power is the chance that a specified analysis would detect an effect of a specified size under its assumptions. A planning calculation depends on the effect chosen, the model, the allocation, the significance level, and other assumptions. It should not be mistaken for evidence that a study did or did not detect an effect. In this case, the primary response estimate is not reported in the registry record, so the observed effect underlying the stated illustrations cannot be examined from the endpoint results. The record does not report a protocol sample-size justification or the statistical plan used for the trial.

Why do analysis details matter?

General explanation: an analysis population defines who contributes to a particular estimate. The endpoint description says all eligible and treated patients are included, but it does not provide a participant flow, the number with endpoint data, or the handling of withdrawals and missing assessments. Those details affect how a response proportion should be understood. For example, if some participants lack measurements, the analysis rule determines whether they are excluded, classified in a particular way, or addressed by another method. No such rule is reported in the registry record.

Likewise, a statistical method needs to be interpreted alongside the outcome definition and the analysis population. The record identifies the type of endpoint and its confidence-interval measure, but not the calculation method, any adjustment, or an analysis result. The absence of those details means a reader cannot reproduce or evaluate the primary endpoint analysis. General statistical concepts can clarify what the planned measures mean, but they cannot substitute for the unreported study-specific estimate and methods.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Rituximab + CHOP")
n      <- c(16)
events <- c(0)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Rituximab + CHOP  16  0  0.0  0.0  20.6  0.0  19.4  0.1  19.5

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome measure, objective response to treatment, and no analyses. It does not report multiple primary comparisons or a multiplicity adjustment. Whether the study considered multiple outcomes or repeated statistical tests in its protocol is not reported in the registry record. General explanation: when several hypotheses are tested, the chance of at least one apparently positive result can increase, and a prespecified approach may be used to address that issue. The available record does not support a study-specific conclusion about multiplicity.

The endpoint description states that all eligible and treated patients are included in the analysis, but does not give a participant flow or the number with observed endpoint data. Missing-data methods, reasons for missing measurements, exclusions after enrollment, and sensitivity analyses are not reported in the registry record. These omissions matter because a proportion based only on participants with available measurements may not represent the full analysis population if missingness is related to outcome.

The record does not report whether assessments were completed according to the scheduled intervals, how the two measurements required for confirmation were selected, or how the primary endpoint was handled for a participant without both measurements. It also does not report an analysis population beyond the general eligibility-and-treatment statement. Thus, the endpoint rule is described, but its operational application and the completeness of its data are unclear.

The record does not report an interim-analysis plan, stopping rule, or statistical analysis plan. These elements should not be inferred from the phase II designation, the pilot-study title, or the terminated status. The reason for termination is also not reported in the registry record. In the absence of these details and a posted analysis, the response outcome cannot be independently assessed for missingness, multiplicity, or analysis-population choices.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutropenia (81.2%), leukopenia (50.0%), lymphopenia (50.0%), infection w/ gr3-4 neutropenia (18.8%), hypotension (12.5%).

The registry's adverse-event information lists one group, Rituximab + CHOP. For serious adverse events, it records 16 at risk and 16 affected; for other adverse events, it also records 16 at risk and 16 affected. These entries describe the registry's group-level fields. They do not provide a comparison with another treatment group, because the study is single-group.

The serious-event terms with listed percentages are neutropenia, 81.2%; leukopenia, 50.0%; lymphopenia, 50.0%; infection with grade 3-4 neutropenia, 18.8%; hypotension, 12.5%; and febrile neutropenia, 12.5%. The registry record does not provide event-level counts for these terms, their timing, duration, severity beyond the term wording, or how repeated events were handled. The percentages should therefore be read as the recorded figures, not as a basis for reconstructing counts or further calculations.

General explanation: safety summaries depend on the event definitions, observation period, and whether figures refer to participants with an event or the number of events. They do not by themselves establish that an intervention caused an event. The registry record does not report a causal attribution method or a comparative safety analysis. These safety entries are distinct from the primary objective-response outcome, whose result is not reported in the registry record.

13. What the Result Does, and Does Not, Mean

The record establishes that this was a phase II pilot study of rituximab plus CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, using objective response as the primary endpoint. It defines response with a laboratory threshold and confirmation measurements, and specifies a 90% confidence interval as the endpoint's dispersion measure. However, it does not report the response estimate, the confidence interval, or any endpoint analysis. There is therefore no posted primary result from which to judge the observed frequency or precision of response.

Even if a single-group response result were available, it would describe outcomes in the treated participants rather than provide a randomized estimate of comparative benefit. A single-group design has no concurrent control arm to distinguish the intervention's contribution from other influences. General statistical interpretation: a measured change following treatment is not, on its own, proof that treatment caused the change. The available record does not support a causal conclusion or a treatment comparison.

The safety record lists serious and other adverse-event group figures and several serious-event terms with percentages. These entries can be described as reported safety information, but they do not establish causation and do not permit a comparison with another regimen. The record does not explain the reason for termination, and that status alone should not be read as evidence of a particular outcome or safety concern.

Accordingly, the defensible reading is limited: the registry documents the intended population, one treatment group, a response definition, an assessment schedule, and safety entries. The primary result and important analysis details are not reported in the registry record. The available information does not establish whether the regimen met the response criterion at any particular rate, how precise an estimate would be, or how outcomes compare with an alternative approach.

14. Why This Trial Matters Statistically

This trial is statistically instructive because its endpoint is clearly defined while its result is absent from the registry record. A precise definition does not replace an estimate: the threshold, confirmation requirement, and confidence-interval specification explain what the study intended to measure, but they cannot show how many participants met the rule or how uncertain that estimate would be.

The record also illustrates why design and analysis answer different questions. A single-group phase II study can describe an outcome among people receiving a regimen. Without a control group, it cannot estimate a randomized contrast. This matters when interpreting any future or separately reported response figure: an observed proportion and a treatment effect are not interchangeable quantities.

Finally, the safety entries show why denominators and event definitions need to accompany percentages. The record gives group-level at-risk and affected fields and selected serious-event percentages, but does not explain all event-level details or provide a comparative analysis. Readers should avoid turning those entries into stronger causal or comparative claims than the design and reporting support.

The main statistical lesson is therefore about evidential limits. The registry makes several design and endpoint features explicit, but it does not report the primary analysis, missing-data handling, or the reason for termination. Transparent definitions are useful; meaningful interpretation also requires results and analysis context.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation in the registry record is the absence of a primary-response result despite the outcome definition and confidence-interval measure being specified. The record lists zero analyses. It does not report the response proportion, the interval, the number meeting the response definition, or the number with evaluable measurements. This prevents assessment of both the observed outcome and its precision.

The study is single-group, has no masking, and lists allocation as NA. There is no like-for-like control comparison, so the design cannot separate outcomes associated with the regimen from other influences. The registry record also does not provide baseline characteristics, participant flow, or details about actual completion of the response-assessment schedule.

The analysis description says all eligible and treated patients are included, but missing-data handling and reasons for missing assessments are not reported in the registry record. Nor are the statistical analysis plan, any interim analyses, or the study's sample-size justification reported. The planning illustrations described in the record are not a substitute for those study-specific methods.

The status is terminated, but the reason is not reported in the registry record. It is therefore not possible to determine from this entry whether termination affected follow-up or endpoint availability. Safety reporting is also limited: the record lists event terms and group figures but does not provide fuller event-level context or a comparative safety analysis. These reporting gaps constrain interpretation without establishing why the information is absent.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia — NCT00060346.
• Registry record last updated 2023-06-29; status last verified 2023-06.
• Results first posted 2013-02-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This phase II pilot study evaluated rituximab plus CHOP in a single group of patients with newly diagnosed Waldenstrom's macroglobulinemia. The registry lists enrollment of 16, no masking, allocation as NA, and status as terminated. It identifies objective response to treatment as the primary endpoint, defined by a greater than 50% reduction in quantitative IgM or M-Spike levels from baseline confirmed by two measurements separated by at least 3 weeks.

The primary outcome result and its 90% confidence interval are not reported in the registry record, and the record lists zero analyses. The reason for termination, missing-data methods, and detailed statistical analysis plan are also not reported. Safety entries list serious and other adverse-event group figures and selected serious-event terms with percentages, but do not provide a comparative assessment. The single-group design supports no randomized treatment comparison.